Cargando…
Novel cancer therapy targeting microbiome
In the human intestinal tract, there are more than 100 trillion symbiotic bacteria, which form the gut microbiota. Approximately 70% of the human immune system is in the intestinal tract, which prevents infection by pathogenic bacteria. When the intestinal microbiota is disturbed, causing dysbiosis,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526180/ https://www.ncbi.nlm.nih.gov/pubmed/31190864 http://dx.doi.org/10.2147/OTT.S207546 |
_version_ | 1783419847802093568 |
---|---|
author | Nagano, Tatsuya Otoshi, Takehiro Hazama, Daisuke Kiriu, Tatsunori Umezawa, Kanoko Katsurada, Naoko Nishimura, Yoshihiro |
author_facet | Nagano, Tatsuya Otoshi, Takehiro Hazama, Daisuke Kiriu, Tatsunori Umezawa, Kanoko Katsurada, Naoko Nishimura, Yoshihiro |
author_sort | Nagano, Tatsuya |
collection | PubMed |
description | In the human intestinal tract, there are more than 100 trillion symbiotic bacteria, which form the gut microbiota. Approximately 70% of the human immune system is in the intestinal tract, which prevents infection by pathogenic bacteria. When the intestinal microbiota is disturbed, causing dysbiosis, it can lead to obesity, diabetes mellitus, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, autism spectrum disorder and cancer. Recent metabolomics analyses have also made the association between the microbiota and carcinogenesis clear. Here, we review the current evidence on the association between the microbiota and gastric, bladder, hepatobiliary, pancreatic, lung and colorectal cancer. Moreover, several animal studies have revealed that probiotics seem to be effective for the prevention of carcinogenesis to some extent. In this review, we focused on this relationship between the microbiota and cancer, and considered how to prevent cancer using strategies involving the gut microbiota. |
format | Online Article Text |
id | pubmed-6526180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65261802019-06-12 Novel cancer therapy targeting microbiome Nagano, Tatsuya Otoshi, Takehiro Hazama, Daisuke Kiriu, Tatsunori Umezawa, Kanoko Katsurada, Naoko Nishimura, Yoshihiro Onco Targets Ther Review In the human intestinal tract, there are more than 100 trillion symbiotic bacteria, which form the gut microbiota. Approximately 70% of the human immune system is in the intestinal tract, which prevents infection by pathogenic bacteria. When the intestinal microbiota is disturbed, causing dysbiosis, it can lead to obesity, diabetes mellitus, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, autism spectrum disorder and cancer. Recent metabolomics analyses have also made the association between the microbiota and carcinogenesis clear. Here, we review the current evidence on the association between the microbiota and gastric, bladder, hepatobiliary, pancreatic, lung and colorectal cancer. Moreover, several animal studies have revealed that probiotics seem to be effective for the prevention of carcinogenesis to some extent. In this review, we focused on this relationship between the microbiota and cancer, and considered how to prevent cancer using strategies involving the gut microbiota. Dove 2019-05-13 /pmc/articles/PMC6526180/ /pubmed/31190864 http://dx.doi.org/10.2147/OTT.S207546 Text en © 2019 Nagano et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Nagano, Tatsuya Otoshi, Takehiro Hazama, Daisuke Kiriu, Tatsunori Umezawa, Kanoko Katsurada, Naoko Nishimura, Yoshihiro Novel cancer therapy targeting microbiome |
title | Novel cancer therapy targeting microbiome |
title_full | Novel cancer therapy targeting microbiome |
title_fullStr | Novel cancer therapy targeting microbiome |
title_full_unstemmed | Novel cancer therapy targeting microbiome |
title_short | Novel cancer therapy targeting microbiome |
title_sort | novel cancer therapy targeting microbiome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526180/ https://www.ncbi.nlm.nih.gov/pubmed/31190864 http://dx.doi.org/10.2147/OTT.S207546 |
work_keys_str_mv | AT naganotatsuya novelcancertherapytargetingmicrobiome AT otoshitakehiro novelcancertherapytargetingmicrobiome AT hazamadaisuke novelcancertherapytargetingmicrobiome AT kiriutatsunori novelcancertherapytargetingmicrobiome AT umezawakanoko novelcancertherapytargetingmicrobiome AT katsuradanaoko novelcancertherapytargetingmicrobiome AT nishimurayoshihiro novelcancertherapytargetingmicrobiome |